InvestorsHub Logo
Followers 1
Posts 160
Boards Moderated 0
Alias Born 10/17/2013

Re: Biobillionair post# 22164

Monday, 11/25/2013 9:48:42 PM

Monday, November 25, 2013 9:48:42 PM

Post# of 426470
BB,

Looking at the primary and secondary outcomes of this study, it seems reasonable that it will only help Vascepa's case. From what I see, this is not a CVE outcomes based trial. I imagine they will see positive effects in the measurements of lipids and inflammation markers. Of course the study results will not be ready until 2016.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News